These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 18399907

  • 1. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal.
    Capoor MR, Mandal P, Deb M, Aggarwal P, Banerjee U.
    Mycoses; 2008 May; 51(3):258-65. PubMed ID: 18399907
    [Abstract] [Full Text] [Related]

  • 2. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ, Wu HC, Hsueh PR.
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [Abstract] [Full Text] [Related]

  • 3. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
    Almeida AM, Matsumoto MT, Baeza LC, de Oliveira E Silva RB, Kleiner AA, Melhem Mde S, Mendes Giannini MJ, Laboratory Group on Cryptococcosis.
    FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
    [Abstract] [Full Text] [Related]

  • 4. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB, Sujatha S, Parija SC.
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [Abstract] [Full Text] [Related]

  • 5. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 6. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, Foongladda S.
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [Abstract] [Full Text] [Related]

  • 7. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
    Souza LK, Souza Junior AH, Costa CR, Faganello J, Vainstein MH, Chagas AL, Souza AC, Silva MR.
    Mycoses; 2010 Jan; 53(1):62-7. PubMed ID: 19500261
    [Abstract] [Full Text] [Related]

  • 8. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y.
    J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
    [Abstract] [Full Text] [Related]

  • 9. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F, Hare Jensen R, Meis JF, Arendrup MC.
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [Abstract] [Full Text] [Related]

  • 10. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
    Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM.
    Rev Iberoam Micol; 2009 Sep 30; 26(3):194-7. PubMed ID: 19635445
    [Abstract] [Full Text] [Related]

  • 11. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
    Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock DW, Cryptococcal Disease Active Surveillance Group.
    Antimicrob Agents Chemother; 2001 Nov 30; 45(11):3065-9. PubMed ID: 11600357
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
    Pappalardo MC, Szeszs MW, Martins MA, Baceti LB, Bonfietti LX, Purisco SU, Baez AA, Melhem MS.
    Diagn Microbiol Infect Dis; 2009 Jun 30; 64(2):146-51. PubMed ID: 19345042
    [Abstract] [Full Text] [Related]

  • 13. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS, Nawange SR, Singh SM, Yadu R, Tiwari A, Gumasta R, Kavishwar A.
    Braz J Microbiol; 2015 Jun 30; 46(4):1125-33. PubMed ID: 26691471
    [Abstract] [Full Text] [Related]

  • 14. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
    Arsic Arsenijevic V, Pekmezovic MG, Meis JF, Hagen F.
    Mycoses; 2014 Jun 30; 57(6):380-7. PubMed ID: 24438323
    [Abstract] [Full Text] [Related]

  • 15. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care.
    Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U.
    J Antimicrob Chemother; 2003 Oct 30; 52(4):683-6. PubMed ID: 12951350
    [Abstract] [Full Text] [Related]

  • 16. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
    Bertout S, Drakulovski P, Kouanfack C, Krasteva D, Ngouana T, Dunyach-Rémy C, Dongtsa J, Aghokeng A, Delaporte E, Koulla-Shiro S, Reynes J, Mallié M.
    Clin Microbiol Infect; 2013 Aug 30; 19(8):763-9. PubMed ID: 23033854
    [Abstract] [Full Text] [Related]

  • 17. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN, Huang CR, Lei CB, Lee PY, Chien CC, Chang HW, Chang CS, Lu CH.
    Jpn J Infect Dis; 2004 Jun 30; 57(3):113-5. PubMed ID: 15218221
    [Abstract] [Full Text] [Related]

  • 18. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.
    J Antimicrob Chemother; 2005 Dec 30; 56(6):1144-7. PubMed ID: 16282208
    [Abstract] [Full Text] [Related]

  • 19. Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates.
    Tintelnot K, Lemmer K, Losert H, Schär G, Polak A.
    Mycoses; 2004 Dec 30; 47(11-12):455-64. PubMed ID: 15601449
    [Abstract] [Full Text] [Related]

  • 20. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA.
    Mycoses; 2005 Sep 30; 48(5):327-32. PubMed ID: 16115103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.